Primary Sclerosing Cholangitis (PSC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Primary sclerosing cholangitis (PSC) is a chronic liver condition characterized by inflammation and fibrosis of the bile ducts. It is closely linked to inflammatory bowel disease (IBD), and the extent of biliary system involvement can vary. Most PSC patients also have underlying IBD, such as ulcerative colitis or Crohn's disease. Ulcerative colitis is more common in PSC patients, accounting for 85% of cases, whereas Crohn's disease is less prevalent at 15%. Approximately 2.5-7.5% of all ulcerative colitis patients may develop PSC. In over 80% of PSC cases, strictures (narrowing of bile ducts) are present both within and outside the liver. However, around 10% only have intrahepatic strictures, and less than 5% have extrahepatic strictures exclusively. Most individuals with PSC are asymptomatic and are typically diagnosed through abnormal liver function tests in routine blood work. Despite advanced disease, many patients remain symptom-free for extended periods. The clinical course of PSC varies widely and is unpredictable. A consistently low serum alkaline phosphatase level (less than 1.5 times the upper normal limit) is associated with a favorable prognosis. Patients with small duct PSC generally have a good prognosis, no documented cases of bile duct malignancy, and progression to severe liver disease is uncommon. The Mayo risk score, incorporating factors like age, serum bilirubin, serum albumin, serum AST, and a history of variceal bleeding, helps predict survival in PSC patients. Currently, there are no FDA-approved medications for treating or curing primary sclerosing cholangitis (PSC).

·       The incidence of primary sclerosing cholangitis ranges between 0.4 and 1.30 cases per 100,000 people per year.

 

Thelansis’s “Primary Sclerosing Cholangitis (PSC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Sclerosing Cholangitis (PSC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Primary Sclerosing Cholangitis (PSC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Primary Sclerosing Cholangitis (PSC) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Primary Sclerosing Cholangitis (PSC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Primary Sclerosing Cholangitis (PSC), Primary Sclerosing Cholangitis (PSC) market outlook, Primary Sclerosing Cholangitis (PSC) competitive landscape, Primary Sclerosing Cholangitis (PSC) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence 

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more